Section of Nephrology, Baylor College of Medicine, Houston, Texas.
Division of Nephrology, The Lundquist Institute at Harbor UCLA Medical Center, West Carson, California.
J Am Soc Nephrol. 2022 Jun;33(6):1063-1072. doi: 10.1681/ASN.2021060854. Epub 2022 Mar 21.
The United States Department of Health and Human Services launched the Advancing American Kidney Health Initiative in 2019, which included a goal of transforming dialysis care from an in-center to a largely home-based dialysis program. A substantial motivator for this transition is the potential to reduce costs of ESKD care with peritoneal dialysis. Studies demonstrating that peritoneal dialysis is less costly than in-center hemodialysis have often focused on the perspective of the payer, whereas less consideration has been given to the costs of those who are more directly involved in treatment decision making, including patients, caregivers, physicians, and dialysis facilities. We review comparisons of peritoneal dialysis and in-center hemodialysis costs, focusing on costs incurred by the people and organizations making decisions about dialysis modality, to highlight the financial barriers toward increased adoption of peritoneal dialysis. We specifically address misaligned economic incentives, underappreciated costs for key stakeholders involved in peritoneal dialysis delivery, differences in provider costs, and transition costs. We conclude by offering policy suggestions that include improving data collection to better understand costs in peritoneal dialysis, and sharing potential savings among all stakeholders, to incentivize a transition to peritoneal dialysis.
美国卫生与公众服务部于 2019 年启动了“推进美国肾脏健康倡议”,其中包括将透析护理从中心式转变为以家庭为基础的透析计划的目标。推动这一转变的一个重要动机是腹膜透析有可能降低终末期肾病治疗的成本。证明腹膜透析比中心血液透析成本更低的研究通常侧重于付款人的角度,而对更直接参与治疗决策的人的成本考虑较少,包括患者、护理人员、医生和透析机构。我们回顾了腹膜透析和中心血液透析成本的比较,重点关注决定透析方式的人和组织所产生的成本,以突出增加腹膜透析采用所面临的财务障碍。我们特别讨论了经济激励措施的错位、腹膜透析提供过程中关键利益相关者的成本被低估、提供者成本的差异以及过渡成本。最后,我们提出了一些政策建议,包括改善数据收集以更好地了解腹膜透析的成本,并在所有利益相关者之间分享潜在的节省,以激励向腹膜透析的转变。